Sharemaestro Newsreel

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity

Earnings Call Insights: Cibus, Inc. (CBUS) Q2 2026 MANAGEMENT VIEW * CEO Craig Wichner framed his priorities around scaling revenue and tighter spending control, saying, "I accepted the job of CEO because I believe we can generate revenue at scale. That is my mission." …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

Dare Bioscience earnings beat by $0.11, revenue topped estimates

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of $-0.2000, surpassing analyst estimates by $0.11, and revenue of $187.55K, significantly beating the consensus estimate of $1.67K. Despite the positive earnings surprise, the company's stock has seen a decline of -36.87% over the last three months …

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares of Stock

Top Kailera Therapeutics (KLRA) Competitors 2026

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme's proprietary ENHANZE drug delivery technology, …

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …

Cibus (NASDAQ:CBUS) Releases Earnings Results

Kura Oncology (KURA) Stock Revenue Growth Clashes With Mounting Losses

Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock

Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Stocks See Support from Favorable PPI Report

The S&P 500 Index ($SPX) (SPY) is up +0.57%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.22%. September E-mini S&P futures (ESU26) are up +0.58%, and September E-mini Nasdaq futures (NQU26) are …

Capricor Therapeutics (NASDAQ:CAPR) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance

Earnings Call Insights: Belite Bio (BLTE) Q2 2026 MANAGEMENT VIEW * Dr. Tom Lin (Chairman of the Board of Directors & CEO) framed the quarter around U.S. regulatory timing, saying, "the FDA has accepted our new drug application for Tinlarebant with priority review and …

Capricor outlines BLA amendment plan as FDA signals willingness to review, with PDUFA date set for August 22

Earnings Call Insights: Capricor Therapeutics (CAPR) Q2 2026 MANAGEMENT VIEW * Linda Marbán (Co-Founder, President, CEO & Director) said the company’s Deramiocel BLA “remains under review with the FDA with a current PDUFA target action date of August 22,” and framed updates around “our …

Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Tarsus Pharmaceuticals stock has delivered a very large 3 year return, yet the broader valuation checks still suggest it trades on the cheap …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Bio-Techne (TECH) Stock Stalls As 61.8x P E Meets Soft Demand

CELCUITY ($CELC) Releases Q2 2026 Earnings

CAPRICOR THERAPEUTICS ($CAPR) Releases Q2 2026 Earnings

Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours

Nektar Therapeutics reported better-than-expected Q2 2026 EPS but a slight revenue miss, causing its stock to slip after hours. The company maintains a strong cash position of over $1 billion, funding clinical development into 2028, and is advancing its lead pipeline asset, REZPEG, through …

Alumis (NASDAQ:ALMS) Issues Earnings Results

Alumis (NASDAQ:ALMS) reported earnings that missed analyst expectations, with an adjusted loss of $1.11 per share against a $0.73 consensus estimate and revenue of $1.66 million versus a $3.47 million forecast. Following the announcement, ALMS shares declined by $1.14 to $24.41. Despite some analyst …

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Laura HansenChief Executive Officer - Ryan WattsChief Commercial Officer - Katie PengChief Operating and Financial Officer - Alexander SchuthChief Medical Officer, Head of Development - …

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. …

Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across …

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced a secondary public offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P., an existing shareholder. BridgeBio itself is not selling any shares and will not receive any proceeds from this offering. William Blair, …

KKR Proposes Sale of 5 Million BridgeBio Pharma Shares in Offering

BridgeBio Pharma (BBIO) announced a secondary public offering of 5,000,000 shares of its common stock, to be sold by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not sell any shares in this transaction and will not receive any proceeds. The offering is subject …

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours

Daré Bioscience reported a narrowed Q2 2026 net loss of $3.0 million, down from $4.0 million year-over-year, with revenue reaching $0.2 million. The company's stock initially fell but then surged 21.2% after hours, as investors reacted positively to progress in commercialization with new product …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips

Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …